Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion for major depressive disorder with reduced positive affect
ChiCTR2300070221Phase 4Not yet recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bupropion in major depressive disorder (MDD) (2 arms), sponsored by Beijing Anding Hospital. Primary endpoint: HAMD-17 low motivation factor. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2300070221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070221.